ST未名：2025年全年净亏损5,500万元—9,000万元

Core Viewpoint - ST Unimed has announced an annual performance forecast indicating a projected net loss attributable to shareholders of the listed company for 2025, estimated between 55 million to 90 million yuan [1] Financial Performance - The expected net profit, excluding non-recurring gains and losses, is projected to be a loss of 70 million to 105 million yuan for the year 2025 [1] - The primary reason for the losses is the suspension of production and sales by its subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., which has significantly impacted related business revenue [1] Operational Challenges - The company is actively working on rectification measures to expedite the resumption of production, but ongoing costs and expenses continue to contribute to the losses [1]